cas 2368945-95-1|| where to buy tert-butyl 5-acetamido-3-bromo-pyrrolo[2,3-c]pyridine-1-carboxylate

製品名:tert-butyl 5-acetamido-3-bromo-pyrrolo[2,3-c]pyridine-1-carboxylate

IUPAC Name:tert-butyl 3-bromo-5-acetamido-1H-pyrrolo[2,3-c]pyridine-1-carboxylate

包装単位	有効在庫	価格（USD）
CM429663-100mg	in stock	ɅɅǕ
CM429663-250mg	in stock	ǧƱɅ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 2368945-95-1 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:2368945-95-1; 分子式:C14H16BrN3O3; 融点:-; SMILESコード:CC(=O)NC1=NC=C2N(C=C(Br)C2=C1)C(=O)OC(C)(C)C; 密度:

: カタログ番号:CM429663; 分子量:354.2; 沸点:; MDL番号:MFCD32670499; 保管方法:

: Azaindoles; Azaindole can be regarded as the biological isostere of indole, and the molecular unit of indole plays a huge role in the life process. Many drug molecules contain indole units. Azaindole is an important heterocyclic intermediate with good biological and medicinal value, and is the core structure of many drugs, such as antitumor drugs, dopamine D4 receptors, kinase inhibitors, thrombin inhibitors, etc. Therefore, it has a wide range of application value in medical research. Azaindole can be regarded as the biological isostere of indole, and the molecular unit of indole plays a huge role in the life process. Many drug molecules contain indole units. Azaindole is an important heterocyclic intermediate with good biological and medicinal value, and is the core structure of many drugs, such as antitumor drugs, dopamine D4 receptors, kinase inhibitors, thrombin inhibitors, etc. Therefore, it has a wide range of application value in medical research.Azaindole

: ABBV-712; TYK2 is an attractive target for various autoimmune diseases as it regulates signal transduction downstream of IL-23 and IL-12 receptors. Selective TYK2 inhibition offers a differentiated clinical profile compared to currently approved JAK inhibitors. Scientists discovered the clinical candidate ABBV-712 in the optimization of selective TYK2 inhibitors targeting the pseudokinase domain.